According to CNBC TV18, N Jayakumar, Group CEO and MD of Prime Securities, believes export manufacturing is positioned to benefit significantly from current market conditions. The weaker rupee and high interest rate environment are creating favorable conditions for Indian manufacturers to compete in global markets. This currency and rate combination is expected to enhance the competitiveness of Indian export-oriented manufacturing sectors.
As reported by CNBC TV18, Jayakumar maintains a positive outlook on the Indian pharmaceutical sector, particularly focusing on generics. He cites global drug shortages as a key factor supporting the sector's growth prospects. The combination of supply constraints in international markets and India's established manufacturing capabilities in generics creates a favorable environment for continued sector expansion.
According to the report, Jayakumar identifies low investor ownership in the pharmaceutical sector as another positive factor. This relatively low ownership structure suggests potential for increased institutional and retail participation, which could support sustained growth in the generics segment. The combination of global supply constraints and domestic market dynamics creates a compelling investment case for Indian pharmaceutical companies.
As reported by CNBC TV18, Jayakumar suggests that pharmaceutical and manufacturing sectors could lead the next growth cycle in the Indian economy. The convergence of favorable currency and interest rate conditions, combined with global supply shortages and India's manufacturing capabilities, positions these sectors for potential outperformance in the coming period. This assessment reflects the current market dynamics supporting export-oriented industries.
